{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T11:58:21Z","timestamp":1772366301772,"version":"3.50.1"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>As life span has increased among patients with cancer, survivorship has become an important component of breast cancer care. Among survivorship concerns, adequate contraceptive counseling is needed for premenopausal patients who are not seeking to become pregnant.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine contraceptive use and chosen methods and to assess factors associated with contraceptive use over time in patients with early breast cancer.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>The Cancer Toxicity (CANTO) study was a multicenter nationwide prospective cohort study that enrolled women diagnosed with stage I to stage III breast cancer in France between March 2012 and December 2017. This analysis included 2900 premenopausal women who were 50 years of age or younger at diagnosis. Data were analyzed from July 2020 to July 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Contraceptive use and method at diagnosis, shortly after the end of primary treatment (year 1), and during follow-up (year 2).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Contraceptive use and methods were longitudinally evaluated at diagnosis, year 1, and year 2 after breast cancer diagnosis. Multivariable logistic regression models were used to assess the associations of clinical, socioeconomic, treatment, adverse effect, and patient-reported outcome variables with contraceptive use after diagnosis.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 2900 patients (mean [SD] age, 43.1 [5.6] years) were included in the analysis; 2050 of 2894 women (70.8%) received chemotherapy, and 2305 of 2880 women (80.0%) received endocrine therapy. After diagnosis, 1182 of 2625 patients (45.0%) at year 1 and 1553 of 2363 patients (65.7%) at year 2 reported consulting with a gynecologist in the previous year. At diagnosis, 1487 of 2744 patients (54.2%) reported contraceptive use, with most patients (921 of 1470 women [62.7%]) using hormonal methods. The use of contraception significantly decreased after diagnosis (911 of 2342 patients [38.9%] at year 1 and 808 of 1961 patients [41.2%] at year 2; P<\/jats:italic>\u2009&amp;lt;\u2009.001 for trend), when most patients (848 of 900 women [94.2%] at year 1 and 767 of 805 women [95.3%] at year 2) reported use of nonhormonal methods; these methods were primarily reversible mechanical approaches (copper intrauterine devices: 656 of 848 patients [77.4%] at year 1 and 577 of 767 patients [75.2%] at year 2; male condoms: 115 of 848 patients [13.6%] at year 1 and 110 of 767 patients [14.3%] at year 2). In the multivariable model, factors significantly associated with contraceptive use at year 1 included using contraception at diagnosis (adjusted odds ratio [aOR], 4.02; 95% CI, 3.15-5.14), being younger (aOR, 1.09; 95% CI, 1.07-1.13 per decreasing year), having better sexual function (aOR, 1.13; 95% CI, 1.07-1.19 per 10-point increment), having children (aOR, 4.21; 95% CI, 1.80-9.86), reporting the presence of leukorrhea (aOR, 1.32; 95% CI, 1.03-1.70), receiving tamoxifen treatment alone (aOR, 1.39; 95% CI, 1.01-1.92), and consulting with a gynecologist in the previous year (aOR, 1.29; 95% CI, 1.02-1.63). Similar factors were associated with contraceptive use at year 2, with the addition of partnered status (aOR, 1.61; 95% CI, 1.07-2.44).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Findings from this study support the importance of raising awareness and improving targeted contraceptive counseling for premenopausal women with early breast cancer.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.33137","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T15:35:13Z","timestamp":1663947313000},"page":"e2233137","source":"Crossref","is-referenced-by-count":22,"title":["Contraceptive Use in Premenopausal Women With Early Breast Cancer"],"prefix":"10.1001","volume":"5","author":[{"given":"Matteo","family":"Lambertini","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy"},{"name":"Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Massarotti","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal, and Child Health, School of Medicine, University of Genova, Genova, Italy"},{"name":"Academic Unit of Obstetrics and Gynaecology, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Havas","sequence":"additional","affiliation":[{"name":"Institut National de la Sante et de la Recherche Medicale Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Pistilli","sequence":"additional","affiliation":[{"name":"Breast Cancer Unit, Medical Oncology Department, Gustave Roussy, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Laure","family":"Martin","sequence":"additional","affiliation":[{"name":"Unicancer, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Jacquet","sequence":"additional","affiliation":[{"name":"Unicancer, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Coutant","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Georges-Fran\u00e7ois Leclerc, Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Coussy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Curie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma Dhaini","family":"M\u00e9rim\u00e8che","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre Les Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Lerebours","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Curie, Saint-Cloud, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Rousset-Jablonski","sequence":"additional","affiliation":[{"name":"Department of Surgery, Centre L\u00e9on Berard, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Jouannaud","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Jean Godinot, Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Rigal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Henri Becquerel, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Fournier","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Institut Bergoni\u00e9, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Soulie","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut de Canc\u00e9rologie de L\u2019ouest-Paul Papin, Angers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Alice","family":"Franzoi","sequence":"additional","affiliation":[{"name":"Breast Cancer Unit, Medical Oncology Department, Gustave Roussy, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy"},{"name":"Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann H.","family":"Partridge","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Andr\u00e9","sequence":"additional","affiliation":[{"name":"Institut National de la Sante et de la Recherche Medicale Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France"},{"name":"Breast Cancer Unit, Medical Oncology Department, Gustave Roussy, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Vaz-Luis","sequence":"additional","affiliation":[{"name":"Institut National de la Sante et de la Recherche Medicale Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France"},{"name":"Breast Cancer Unit, Medical Oncology Department, Gustave Roussy, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Di Meglio","sequence":"additional","affiliation":[{"name":"Institut National de la Sante et de la Recherche Medicale Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France"},{"name":"Breast Cancer Unit, Medical Oncology Department, Gustave Roussy, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"issue":"12","key":"zoi220942r1","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(17)30677-0","article-title":"Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study.","volume":"18","author":"Fidler","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"zoi220942r2","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/annonc\/mdz298","article-title":"Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.","volume":"30","author":"Ferreira","year":"2019","journal-title":"Ann Oncol"},{"issue":"12","key":"zoi220942r3","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","article-title":"Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines.","volume":"31","author":"Lambertini","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"zoi220942r4","doi-asserted-by":"publisher","DOI":"10.1093\/hropen\/hoaa052","article-title":"ESHRE guideline: female fertility preservation.","volume":"2020","author":"Anderson","year":"2020","journal-title":"Hum Reprod Open"},{"issue":"2","key":"zoi220942r5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/humupd\/dmy038","article-title":"How can we improve oncofertility care for patients? a systematic scoping review of current international practice and models of care.","volume":"25","author":"Anazodo","year":"2019","journal-title":"Hum Reprod Update"},{"issue":"6","key":"zoi220942r6","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.fertnstert.2018.03.004","article-title":"Contraception and reproductive health counseling in cancer survivorship\u2014plan A rather than plan B.","volume":"109","author":"Nahata","year":"2018","journal-title":"Fertil Steril"},{"issue":"8","key":"zoi220942r7","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/humrep\/dez108","article-title":"Beyond fertility preservation: role of the oncofertility unit in the reproductive and gynecological follow-up of young cancer patients.","volume":"34","author":"Massarotti","year":"2019","journal-title":"Hum Reprod"},{"issue":"29","key":"zoi220942r8","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/JCO.21.00535","article-title":"Pregnancy after breast cancer: a systematic review and meta-analysis.","volume":"39","author":"Lambertini","year":"2021","journal-title":"J Clin Oncol"},{"key":"zoi220942r9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.breast.2019.05.004","article-title":"Planned and unplanned pregnancies in breast cancer survivors.","volume":"46","author":"Kopeika","year":"2019","journal-title":"Breast"},{"issue":"7","key":"zoi220942r10","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/cncr.v127.7","article-title":"Pregnancy after breast cancer: results from a prospective cohort of young women with breast cancer.","volume":"127","author":"Poorvu","year":"2021","journal-title":"Cancer"},{"issue":"6","key":"zoi220942r11","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.fertnstert.2018.02.136","article-title":"Use of emergency contraception among female young adult cancer survivors.","volume":"109","author":"Medica","year":"2018","journal-title":"Fertil Steril"},{"key":"zoi220942r12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.breast.2015.10.003","article-title":"Contraception counseling for young breast cancer patients: a practical needs assessment and a survey among medical oncologists.","volume":"30","author":"G\u00fcth","year":"2016","journal-title":"Breast"},{"key":"zoi220942r13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.18.00064","article-title":"Suboptimal use of effective contraceptive methods in young Mexican women with breast cancer.","volume":"4","author":"Castro-Sanchez","year":"2018","journal-title":"J Glob Oncol"},{"issue":"4","key":"zoi220942r14","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.fertnstert.2018.12.016","article-title":"Perceived infertility and contraceptive use in the female, reproductive-age cancer survivor.","volume":"111","author":"Hadnott","year":"2019","journal-title":"Fertil Steril"},{"issue":"4","key":"zoi220942r15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nrclinonc.2017.207","article-title":"Exogenous reproductive hormone use in breast cancer survivors and previvors.","volume":"15","author":"Vaz-Luis","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"zoi220942r16","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s11764-019-00765-x","article-title":"Contraceptive utilization and counseling among breast cancer survivors.","volume":"13","author":"Mody","year":"2019","journal-title":"J Cancer Surviv"},{"issue":"5","key":"zoi220942r17","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.contraception.2014.01.014","article-title":"Contraception after cancer treatment: describing methods, counseling, and unintended pregnancy risk.","volume":"89","author":"Quinn","year":"2014","journal-title":"Contraception"},{"issue":"3","key":"zoi220942r18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/AOG.0000000000000963","article-title":"Contraceptive practices among female cancer survivors of reproductive age.","volume":"126","author":"Dominick","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"5","key":"zoi220942r19","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000562","article-title":"UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO).","volume":"4","author":"Vaz-Luis","year":"2019","journal-title":"ESMO Open"},{"issue":"9596","key":"zoi220942r20","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"zoi220942r22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/BF00434800","article-title":"The European Organization for Research and Treatment of Cancer. approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life.","volume":"2","author":"Sprangers","year":"1993","journal-title":"Qual Life Res"},{"issue":"5","key":"zoi220942r23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"zoi220942r27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw099"},{"key":"zoi220942r28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01252"},{"key":"zoi220942r29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01958"},{"issue":"6","key":"zoi220942r30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/acp.1983.67.issue-6","article-title":"The Hospital Anxiety and Depression Scale.","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"issue":"12","key":"zoi220942r32","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1111\/jsm.12686","article-title":"Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women\u2019s Sexual Health and the North American Menopause Society.","volume":"11","author":"Portman","year":"2014","journal-title":"J Sex Med"},{"issue":"1","key":"zoi220942r33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.contraception.2017.10.003","article-title":"Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014.","volume":"97","author":"Kavanaugh","year":"2018","journal-title":"Contraception"},{"issue":"6","key":"zoi220942r34","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/13697137.2018.1526893","article-title":"Sexual quality of life in men and women after cancer.","volume":"22","author":"Schover","year":"2019","journal-title":"Climacteric"},{"issue":"9967","key":"zoi220942r35","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S0140-6736(15)60201-X","article-title":"Contraception is as important as fertility preservation in young women with cancer.","volume":"385","author":"Han","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"zoi220942r36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.contraception.2014.03.002","article-title":"Contraceptive use and the role of contraceptive counseling in reproductive-aged women with cancer.","volume":"90","author":"Maslow","year":"2014","journal-title":"Contraception"},{"key":"zoi220942r37","doi-asserted-by":"publisher","author":"Arecco","DOI":"10.1093\/humrep\/deac035"},{"issue":"2","key":"zoi220942r38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10549-021-06436-9","article-title":"Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis.","volume":"191","author":"Poggio","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"zoi220942r39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6503a1","article-title":"U.S. medical eligibility criteria for contraceptive use, 2016.","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"zoi220942r40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/13625187.2019.1602721","article-title":"Contraception in cancer survivors\u2014an expert review part I: breast and gynaecological cancers.","volume":"24","author":"Gompel","year":"2019","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"2","key":"zoi220942r41","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1097\/AOG.0000000000003072","article-title":"ACOG practice bulletin No. 206: use of hormonal contraception in women with coexisting medical conditions.","volume":"133","author":"American College of Obstetricians and Gynecologists.","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"6","key":"zoi220942r42","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/13625187.2018.1535653","article-title":"Two year continuation rates of contraceptive methods in France: a cohort study from the French national health insurance database.","volume":"23","author":"Agostini","year":"2018","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"12","key":"zoi220942r43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","article-title":"Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.","volume":"2015","author":"Dominick","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"zoi220942r44","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1177\/1933719113503408","article-title":"Levonorgestrel intrauterine system in adjuvant tamoxifen treatment: balance of breast risks and endometrial benefits\u2014systematic review of literature.","volume":"21","author":"Gizzo","year":"2014","journal-title":"Reprod Sci"},{"issue":"12","key":"zoi220942r45","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1200\/JCO.19.02242","article-title":"Improving adjuvant endocrine treatment tailoring in premenopausal women with hormone receptor\u2013positive breast cancer.","volume":"38","author":"Lambertini","year":"2020","journal-title":"J Clin Oncol"},{"issue":"21","key":"zoi220942r46","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMoa1110855","article-title":"Effectiveness of long-acting reversible contraception.","volume":"366","author":"Winner","year":"2012","journal-title":"N Engl J Med"},{"key":"zoi220942r21","unstructured":"World Health Organization. Global Physical Activity Questionnaire (GPAQ). World Health Organization. November 13, 2021. Accessed July 10, 2022. https:\/\/www.who.int\/publications\/m\/item\/global-physical-activity-questionnaire"},{"key":"zoi220942r24","unstructured":"European Organization for the Research and Treatment of Cancer. Questionnaires: quality of life of cancer patients. EORTC.org. Accessed July 10, 2022. https:\/\/qol.eortc.org\/questionnaire\/eortc-qlq-c30\/"},{"key":"zoi220942r25","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A; EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual. 3rd ed. European Organisation for Research and Treatment of Cancer; 2001. Accessed July 10, 2022. https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf"},{"key":"zoi220942r26","unstructured":"Scott NW, Fayers PM, Aaronson NK, et al; EORTC Quality of Life Group. EORTC QLQ-C30 Reference Values. European Organisation for Research and Treatment of Cancer; July 2008. Accessed July 10, 2022. https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/reference_values_manual2008.pdf"},{"key":"zoi220942r31","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. National Institutes of Health, US Department of Health and Human Services. May 28, 2009. Accessed July 10, 2022. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2796642\/lambertini_2022_oi_220942_1663342831.87036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T15:35:21Z","timestamp":1663947321000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2796642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.33137","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]}}}